-
1by Mattarocci, Stefano Shyian, Maksym Lemmens, Laure Damay, Pascal Altintas, Dogus Murat Shi, Tianlai Bartholomew, Clinton R Thomä, Nicolas H Hardy, Christopher F J Shore, David Published in Cell reports (Cambridge) (10.04.2014)“...The Rif1 protein, originally identified as a telomere-binding factor in yeast, has recently been implicated in DNA replication control from yeast to metazoans...”
-
2by Mattarocci, Stefano Reinert, Julia K Bunker, Richard D Fontana, Gabriele A Shi, Tianlai Klein, Dominique Cavadini, Simone Faty, Mahamadou Shyian, Maksym Hafner, Lukas Shore, David Thomä, Nicolas H Rass, Ulrich Published in Nature structural & molecular biology (01.07.2017)“...In yeast, Rif1 is part of the telosome, where it inhibits telomerase and checkpoint signaling at chromosome ends. In mammalian cells, Rif1 is not telomeric,...”
-
3by Javanbakht, Hassan Mueller, Henrik Walther, Johanna Zhou, Xue Lopez, Anaïs Pattupara, Thushara Blaising, Julie Pedersen, Lykke Albæk, Nanna Jackerott, Malene Shi, Tianlai Ploix, Corinne Driessen, Wouter Persson, Robert Ravn, Jacob Young, John A.T Ottosen, Søren Published in Molecular therapy. Nucleic acids (01.06.2018)“...Chronic hepatitis B infection (CHB) is an area of high unmet medical need. Current standard-of-care therapies only rarely lead to a functional cure, defined as...”
-
5by Mecate-Zambrano, Angeles Sukumar, Swathi Seebohm, Guiscard Ciminski, Kevin Schreiber, Andre Anhlan, Darisuren Greune, Lilo Wixler, Ludmilla Grothe, Stephanie Stein, Nora Caroline Schmidt, M. Alexander Langer, Klaus Schwemmle, Martin Shi, Tianlai Ludwig, Stephan Boergeling, Yvonne“...Small RNA viruses only have a very limited coding capacity, thus most viral proteins have evolved to fulfill multiple functions. The highly conserved matrix...”
edited by Fontoura, Beatriz M
Published in PLoS pathogens (31.08.2020)
-
6by Kristoffersson, Anders N Bissantz, Caterina Okujava, Rusudan Haldimann, Andreas Walter, Isabelle Shi, Tianlai Zampaloni, Claudia Nielsen, Elisabet I Published in Journal of antimicrobial chemotherapy (01.02.2020)“...Abstract Background Diazabicyclooctanes (DBOs) are an increasingly important group of non β-lactam β-lactamase inhibitors, employed clinically in combinations...”
-
7by Shi, Tianlai Bunker, Richard D Mattarocci, Stefano Ribeyre, Cyril Faty, Mahamadou Gut, Heinz Scrima, Andrea Rass, Ulrich Rubin, Seth M Shore, David Thomä, Nicolas H Published in Cell (Cambridge) (06.06.2013)“...Yeast telomeres comprise irregular TG1-3 DNA repeats bound by the general transcription factor Rap1. Rif1 and Rif2, along with Rap1, form the telosome, a...”
-
8by SHI, Tianlai“...The present invention provides a method for identifying a substance capable of inhibiting at least one activity of an RNA-dependent RNA polymerase (RdRp)...”
07.02.2019
-
9by SHI, Tianlai“...The present invention provides a method for identifying a substance capable of inhibiting at least one activity of an RNA-dependent RNA polymerase (RdRp)...”
12.12.2018
-
10by SHI, Tianlai“...The present invention provides a method for identifying a substance capable of inhibiting at least one activity of an RNA-dependent RNA polymerase (RdRp)...”
10.08.2017
-
11by Shi, Tianlai Bunker, Richard D Mattarocci, Stefano Ribeyre, Cyril Faty, Mahamadou Gut, Heinz Scrima, Andrea Rass, Ulrich Rubin, Seth M Shore, David Thomä, Nicolas H Published in Cell (Cambridge)“...Yeast telomeres comprise irregular TG₁₋₃ DNA repeats bound by the general transcription factor Rap1. Rif1 and Rif2, along with Rap1, form the telosome, a...”
-
12by Kristoffersson, Anders N Bissantz, Caterina Okujava, Rusudan Haldimann, Andreas Walter, Isabelle Shi, Tianlai Zampaloni, Claudia Nielsen, Elisabet I Published in Journal of Antimicrobial Chemotherapy (2020)“...BACKGROUND: Diazabicyclooctanes (DBOs) are an increasingly important group of non β-lactam β-lactamase inhibitors, employed clinically in combinations such as...”
-
13“...The present invention relates to a specific compound having the formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph,...”
-
14by WU, Jun SHEN, Hong CUMMING, John Graham WANG, Lisha TAN, Xuefei LIU, Yongfu SHI, Tianlai“...Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal,...”
10.08.2017
-
15by WU, Jun SHEN, Hong ZBINDEN, Katrin Groebke WANG, Lisha TAN, Xuefei KUHN, Bernd LIU, Yongfu SHI, Tianlai“...The present invention relates to a compound having the formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug,...”
10.08.2017
-
16by WU, Jun SHEN, Hong LI, Dongbo CUMMING, John Graham WANG, Lisha TAN, Xuefei LIU, Yongfu SHI, Tianlai“...Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal,...”
10.08.2017
-
17by WU, Jun SHEN, Hong ZBINDEN, Katrin Groebke NEIDHART, Werner WANG, Lisha TAN, Xuefei LIU, Yongfu KUHN, Bernd SHI, Tianlai“...The present invention relates to a compound having the formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug,...”
10.08.2017
-
18by WU, Jun SHEN, Hong ZBINDEN, Katrin Groebke TANG, Guozhi QIU, Zongxing WANG, Lisha TAN, Xuefei LIU, Yongfu KUHN, Bernd WU, Guolong SHI, Tianlai“...Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal,...”
10.08.2017
-
19by WU, Jun SHEN, Hong LI, Dongbo NEIDHART, Werner WANG, Lisha TAN, Xuefei LIU, Yongfu SHI, Tianlai WU, Guolong“...Provided herein is a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, polymorph, prodrug, codrug, cocrystal,...”
10.08.2017
-
20“...Telomeres form the ends of eukaryotic linear chromosomes and are composed of specialized nucleoprotein complexes. They have been the subject of intense...”